Adimmune, your trusted partner to global market
We tailor our services to customers’ needs and offer solutions for various scales, phases, and timelines. We are one of the key suppliers of high-quality vaccines and biologics around the world.
View All
Support Resilient
Supply for Vaccines
We engage with the WHO Pandemic Influenza Preparedness Framework to foster the development and access to vaccines. Recognized by US FDA and the EU, we tackle health challenges by leveraging our high standards of quality.
.JPG)
04 May. 2026
Capacity Expansion Program Launched as Line 2 Joins International Contract Manufacturing
Adimmune Corporation (TWSE: 4142) today announced that its second automated aseptic filling and packaging line has successfully completed GMP inspection by the U.S. Food and Drug Administration (FDA). The company has also received formal notification from its international partner, Sanofi, to commence parallel production using both Line 1 and Line 2 starting in June. This expansion will double production capacity from 5 million to 10 million doses, with output from international contract manufacturing projects expected to increase significantly year-over-year.
14 Apr. 2026
Adimmune Adds Third GMP Production Line Focused on High-Value, Small-Batch Manufacturing
Adimmune Corporation (TWSE: 4142) today announced that its newly expanded third automated aseptic filling line has passed inspection by Taiwan’s Food and Drug Administration and has been certified as compliant with Good Manufacturing Practice (GMP). The new line utilizes single-use disposable filling assemblies, enabling high-value, small-batch, and diversified production.
17 Mar. 2026
Strong Growth Outlook Drives 150% Oversubscription of Adimmune’s Syndicated Loan
Adimmune Corporation (TWSE: 4142) today signed a NT$4.5 billion syndicated loan agreement with a consortium of ten banks led by Land Bank of Taiwan. Reflecting strong confidence in Adimmune’s growth prospects and recognition of vaccines as a strategically critical industry, the facility was oversubscribed by 150%, demonstrating robust support from the financial sector.
